美国 · SEC FORM 4
DAXOR CORP
DXR · Nasdaq · CIK 0000027367 · Closed-End Funds · Medical Instruments & Supplies
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
4 同一窗口内观察到的 Form 4 交易行
0 sales · 4 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
最新留档分数
- 40.9
- 40.8
- 40.8
- 40.8
- 40.8
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 6,959
- 上期报告
- 2,331
- 日均成交量
- 38,746
- 回补天数
- ≤ 1.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-08 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 1,000 | USD 9.07 | USD 9,070 | SEC 申报 ↗ |
| 2026-03-31 | Michel Robert J | 买入 (P) | Daxor Common Stock | 1,000 | USD 9.90 | USD 9,900 | SEC 申报 ↗ |
| 2026-03-20 | Jefferies John | 买入 (P) | Daxor Common Stock | 5,941 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Michel Robert J | 买入 (P) | Daxor Common Stock | 3,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Feldschuh Jonathan Adam | 买入 (P) | Daxor Common Stock | 18,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-12 | Jefferies John | 买入 (P) | Daxor Common Stock | 2,344 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-04-04 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 2,063 | USD 7.89 | USD 16,277 | SEC 申报 ↗ |
| 2025-03-10 | Michel Robert J | 买入 (P) | Daxor Common Stock | 1,000 | USD 8.00 | USD 8,000 | SEC 申报 ↗ |
| 2025-03-10 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 3,360 | USD 7.68 | USD 25,805 | SEC 申报 ↗ |
| 2024-12-06 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 45,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2024-12-06 | Feldschuh Jonathan Adam | 买入 (P) | Daxor Common Stock | 32,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2024-03-27 | Michel Robert J | 买入 (P) | Daxor Common Stock | 750 | USD 8.70 | USD 6,525 | SEC 申报 ↗ |
| 2024-03-26 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 1,000 | USD 8.13 | USD 8,130 | SEC 申报 ↗ |
| 2024-03-19 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 647 | USD 8.15 | USD 5,273 | SEC 申报 ↗ |
| 2024-03-10 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 1,492 | USD 7.72 | USD 11,518 | SEC 申报 ↗ |
Form 4 申报证据
11 transaction lines in the latest 365-day window; 41 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | Jefferies John | 奖励/授予 (A) | Daxor Common Stock | 2,451 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-23 | Michel Robert J | 奖励/授予 (A) | Daxor Common Stock | 12,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-23 | Feldschuh Michael Richard | 奖励/授予 (A) | Daxor Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (10 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | Jefferies John | 奖励/授予 (A) | Daxor Common Stock | 2,451 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-23 | Michel Robert J | 奖励/授予 (A) | Daxor Common Stock | 12,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-23 | Feldschuh Michael Richard | 奖励/授予 (A) | Daxor Common Stock | 30,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-23 | Feldschuh Jonathan Adam | 奖励/授予 (A) | Daxor Common Stock | 25,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-08 | Feldschuh Michael Richard | 买入 (P) | Daxor Common Stock | 1,000 | USD 9.07 | USD 9,070 | SEC 申报 ↗ |
| 2026-03-31 | Michel Robert J | 买入 (P) | Daxor Common Stock | 1,000 | USD 9.90 | USD 9,900 | SEC 申报 ↗ |
| 2026-03-20 | Jefferies John | 买入 (P) | Daxor Common Stock | 5,941 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Michel Robert J | 买入 (P) | Daxor Common Stock | 3,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-09 | Feldschuh Jonathan Adam | 买入 (P) | Daxor Common Stock | 18,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-12 | Jefferies John | 买入 (P) | Daxor Common Stock | 2,344 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | DXR |
| CIK | 0000027367 |
| 行业 | Closed-End Funds |
| 细分行业 | Medical Instruments & Supplies Yahoo Finance |
| SEC SIC | Investment company (SEC forms N-2, N-2/A, N-CEN) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 41 transaction lines from 2020-07-22 to 2026-08-28 31 P purchase lines · 0 S sale lines · 10 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.